A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients

Giorgia Massacci(University of Rome Tor Vergata), Francesca Sacco(Università Cattolica del Sacro Cuore), Giusj Monia Pugliese(Istituto Superiore di Sanità), Sara Latini(University of Rome Tor Vergata), Livia Perfetto(Sapienza University of Rome), Thomas Fischer(University Hospital Magdeburg), Veronica Venafra(University of Rome Tor Vergata), Natalie Krahmer(Helmholtz Zentrum München), Valeria Bica(University of Rome Tor Vergata), Dimitrios Mougiakakos(Otto-von-Guericke-Universität Magdeburg), Martin Boettcher(Universitätsklinikum Erlangen), Felix Klingelhuber(Deutsches Diabetes-Zentrum e.V.)
bioRxiv (Cold Spring Harbor Laboratory)
May 16, 2022
10.1101/2022.05.16.492070
Cited by 1

Related Papers

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network
|The Lancet|2016|401
CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours
|Nature|2023|296
Advancements and challenges in CAR T cell therapy in autoimmune diseases
|Nature Reviews Rheumatology|2024|203
Apoptotic brown adipocytes enhance energy expenditure via extracellular inosine
|Nature|2022|151
Anti-CD19 CAR T cells for refractory myasthenia gravis
|The Lancet Neurology|2023|147